Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOD5Y0)

Drug Name
Dilazep Drug Info
Synonyms
Dilazep; 35898-87-4; Dilazep [INN]; Dilazepum [INN-Latin]; UNII-F8KLC2BD5Z; Dilazepam [INN-Spanish]; F8KLC2BD5Z; CHEMBL126075; Dilazep (INN); Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester; NCGC00016747-03; AS 05; DSSTox_RID_80871; DSSTox_CID_25425; DSSTox_GSID_45425; Dilazepum; Dilazepam; Tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropanol 3,4,5-trimethoxybenzoate (diester); 3-{4-[3-(3,4,5-trimethoxybenzoyloxy)propyl]-1,4-diazepan-1-yl}propyl 3,4,5-trimethoxybenzoate
Cross-matching ID
PubChem CID
3074
ChEBI ID
CHEMBL126075
CAS Number
CAS 35898-87-4
TTD Drug ID
D00GUM
VARIDT Drug ID
DR00479

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.16 0.00e+0 19/20 (95%) MSMO1;SQLE;SC5D;...
Pentose phosphate pathway 1.89 1.36e-2 25/30 (83.33%) GPI;TKT;ALDOC;...
Arginine biosynthesis 1.89 1.21e-2 17/22 (77.27%) ASS1;CPS1;GLUL;...
Ovarian steroidogenesis 1.86 2.04e-2 41/51 (80.39%) INSR;ADCY1;STAR;...
Complement and coagulation cascades 1.82 2.18e-2 76/85 (89.41%) C7;CFH;FGG;...
Glycine, serine and threonine metabolism 1.79 2.42e-2 31/40 (77.5%) PGAM1;PIPOX;ALDH7A1;...
Alanine, aspartate and glutamate metabolism 1.77 2.59e-2 27/37 (72.97%) ASS1;CPS1;GLUL;...
Glyoxylate and dicarboxylate metabolism 1.72 4.19e-2 23/30 (76.67%) ACAT2;GLUL;MMUT;...
Fructose and mannose metabolism 1.72 3.73e-2 30/33 (90.91%) ALDOC;PFKFB3;KHK;...
Oxidative phosphorylation 1.67 4.98e-2 93/133 (69.92%) ATP6V1H;COX5B;COX6C;...
Toxoplasmosis -1.61 4.99e-2 103/112 (91.96%) JAK2;CIITA;TLR4;...
Tuberculosis -1.67 3.30e-2 159/180 (88.33%) JAK2;CIITA;FCGR3B;...
Human immunodeficiency virus 1 infection -1.70 2.66e-2 189/212 (89.15%) APOBEC3C;JUN;CD4;...
Phagosome -1.72 2.01e-2 118/152 (77.63%) FCGR3B;TLR4;TUBB;...
Apoptosis -1.72 2.13e-2 126/168 (75%) FAS;TRADD;IKBKG;...
Epstein-Barr virus infection -1.77 1.37e-2 189/202 (93.56%) CD58;ITGAL;IFNB1;...
Th17 cell differentiation -1.79 9.52e-3 95/107 (88.79%) CD3E;LCK;NFKB1;...
Th1 and Th2 cell differentiation -1.80 7.06e-3 80/92 (86.96%) TBX21;CD247;PPP3R1;...
Intestinal immune network for IgA production -1.81 5.92e-3 38/48 (79.17%) HLA-DRB1;CD40;TGFB1;...
Influenza A -1.83 6.41e-3 156/172 (90.7%) CXCL8;JAK2;CIITA;...
Herpes simplex virus 1 infection -1.84 5.99e-3 165/498 (33.13%) TP53;TNFRSF14;JAK2;...
Leishmaniasis -1.90 2.20e-3 67/77 (87.01%) NFKBIA;ITGAM;MAPK14;...
Antigen processing and presentation -2.02 0.00e+0 60/78 (76.92%) KIR3DL1;HLA-F;HLA-DRB1;...
Graft-versus-host disease -2.06 0.00e+0 32/42 (76.19%) KIR3DL1;HLA-F;HLA-DRB1;...
Type I diabetes mellitus -2.06 0.00e+0 38/43 (88.37%) HLA-F;HLA-DRB1;HLA-E;...
Viral myocarditis -2.06 0.00e+0 53/60 (88.33%) ACTB;RAC2;RAC3;...
Hematopoietic cell lineage -2.08 0.00e+0 90/99 (90.91%) CD8B;CD34;HLA-DRA;...
RIG-I-like receptor signaling pathway -2.08 0.00e+0 64/70 (91.43%) IFNB1;MAP3K1;NFKB1;...
Asthma -2.14 0.00e+0 25/31 (80.65%) HLA-DOA;IL9;MS4A2;...
Allograft rejection -2.19 0.00e+0 32/38 (84.21%) HLA-F;HLA-DRB1;HLA-E;...
Autoimmune thyroid disease -2.51 0.00e+0 46/53 (86.79%) CTLA4;HLA-F;HLA-DRB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H